BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:30 PM
 | 
Sep 27, 2012
 |  BC Extra  |  Company News

NeuroSearch sells Huntexil to Teva

NeuroSearch A/S (CSE:NEUR) gained DKK1.05 (28%) to DKK4.80 on Thursday after selling Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) rights to Huntington's disease compound Huntexil pridopidine for DKK150 million ($26.1 million) up front, plus a potential DKK55 million ($9.6 million) in regulatory and commercial milestones. Teva said it believes Huntexil "holds promise for...

Read the full 247 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >